HeartSciences Inc. (HSCSW)
| Market Cap | 8.54M +127.0% |
| Revenue (ttm) | 8,669 -76.6% |
| Net Income | -8.49M |
| EPS | -4.03 |
| Shares Out | 3.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 406 |
| Open | 0.0600 |
| Previous Close | 0.0504 |
| Day's Range | 0.0600 - 0.0733 |
| 52-Week Range | 0.0349 - 0.1787 |
| Beta | 1.79 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 24, 2026 |
About HSCSW
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVist... [Read more]
News
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on July 10, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on June 24, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences, Fortitude announces business combination
Fortitude Mining Holdings and HeartSciences (HSCS) announced that they have entered into a definitive merger agreement to combine in an all-stock transaction which is expected to close in H2 2026.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
Fortitude and HeartSciences (Nasdaq: HSCS) Announce Business Combination, Aiming to Bring a Leading Vertically-Integrated Zcash Mining Platform to the Public Markets
FAIRPORT, N.Y.--(BUSINESS WIRE)--Fortitude Mining Holdings, Inc. ("Fortitude"), a vertically-integrated digital asset mining platform anchored in Zcash, and HeartSciences Inc. (Nasdaq: HSCS) (“HeartSc...
HeartSciences Slides: Investor presentation
HeartSciences has posted slides in relation to its latest quarterly earnings report, which was published on June 23, 2026.
HeartSciences granted European patent for heart-monitoring technology
HeartSciences (HSCS) announced that the European Patent Office has granted the company a patent titled “Electrocardiogram-Based Assessment of Diastolic Function.” The patent covers machine-learning mo...
European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences' Patent Portfolio to More Than 45 Granted Patents
Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Patent covers machine-learning models that use ECG data to estimate echoc...
HeartSciences Launches MyoVista Insights™ Version 1.3 with AI-ECG Algorithm Marketplace and First FDA-Cleared Algorithm
Bunkerhill Health's FDA-cleared ECG-EF algorithm for the detection of reduced ejection fraction becomes the first cleared AI-ECG algorithm available through MyoVista Insights, advancing HeartSciences'...
HeartSciences enters commercial agreement with North Shore Health
HeartSciences (HSCS) announced that it has entered into a commercial agreement with North Shore Health, a community hospital serving Cook County, Minnesota and the surrounding region, to deploy the My...
HeartSciences Signs Commercial Agreement with North Shore Health, the First Hospital Deployment from the Cibolo Health Network
Agreement follows Cibolo Health's endorsement of MyoVista Insights for its network of 127 independent hospitals and reflects continued commercial momentum for HeartSciences' ECG management platform Ag...
HeartSciences signs MyoVista commercial agreement with St. Vincent Health
HeartSciences (HSCS) announced that it has signed a commercial agreement with St. Vincent Health to deploy the MyoVista Insights platform.
HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
Agreement with St. Vincent Health marks HeartSciences' transition from early adopter installations to commercial SaaS deployments following the full launch of MyoVista Insights at the American College...
HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
Southlake, TX, April 14, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) a healthcare information technology (“HIT”) company focused on advancing e...
HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category
Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advanci...
HeartSciences to Present at Investor Summit Group Virtual Conference and Host Virtual One on One Investor Meetings
Southlake, TX, March 24, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancin...
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on March 19, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on March 17, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Southlake, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advan...
HeartSciences Quarterly report: Q3 2026
HeartSciences has published its Q3 2026 quarterly earnings report on March 16, 2026.